Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Visiodoron Euphrasia comp. eye ointment is an anthroposophic and homeopathic medicinal product developed by Weleda AG. It is a botanical combination therapy containing three primary active herbal ingredients: *Echinacea angustifolia* (coneflower), *Euphrasia* (eyebright), and *Calendula officinalis* (marigold). The product is specifically indicated for the treatment of non-severe eye inflammations, including conjunctivitis, blepharitis (eyelid margin inflammation), hordeolum (stye), and chalazion. Formulated as a preservative-free ointment, it is designed for topical ophthalmic application, particularly for nighttime use to provide prolonged contact with the ocular surface. As an anthroposophic preparation, it aims to stimulate the body's inherent self-healing processes to resolve inflammation and soothe irritation without targeting a single specific molecular pathway.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Visiodoron Euphrasia comp..